Quality of life analysis measured with the Cervantes 16 scale in treated menopausal women with genitourinary syndrome

J Comp Eff Res. 2022 Dec;11(18):1365-1374. doi: 10.2217/cer-2022-0086. Epub 2022 Nov 4.

Abstract

Aim: To assess the quality of life of menopausal women with genitourinary syndrome receiving local drugs (prasterone, estriol or promestriene). Methods: Prospective, longitudinal, randomized study in which quality of life was assessed using the 16-item Cervantes scale (EC16) before and after treatment. Results: A total of 45 women were assessed (35.6% received prasterone, 33.3% estriol and 31.1% promestriene). After treatment, statistically significant mean score differences were observed in EC16, mainly with prasterone. Improvement in EC16 score only shows a statistically significant relationship with age and drug use. Conclusion: The EC16 is an affordable and quick-to-apply tool that allows physicians and patients to know patients' self-perceived quality of life. Local treatment has been shown to improve the quality of life of menopausal patients with genitourinary syndrome.

Keywords: Cervantes scale; local estrogens; quality of life; vaginal health.

MeSH terms

  • Estriol
  • Female
  • Humans
  • Menopause*
  • Prospective Studies
  • Quality of Life*

Substances

  • Estriol